PPBT
パーブル・バイオテック
Purple Biotech Ltd.
閉場中RVOL 0.9xDV $48,79020日平均DV $52,365?
Earnings 2027-02-1052W high -81.1%52W low +84.6%Fwd PER 24.0xMarket cap $231,981Avg volume 31K
Company Overview
Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q2 | 0.04 | $0 | -$3M |
| 2026 Q1 | 0.00 | $0 | -$3M |
| 2025 Q4 | -1.98 | $0 | -$1M |
| 2025 Q3 | -0.28 | $0 | -$1M |
| 2025 Q2 | -0.40 | $0 | -$2M |
| 2025 Q1 | -0.18 | $0 | -$2M |
| 2024 Q4 |
Beta access -> Sign in with an invite code